financetom
Business
financetom
/
Business
/
International Labour Organisation seeks better working conditions for key workers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
International Labour Organisation seeks better working conditions for key workers
Mar 18, 2023 10:14 AM

The International Labour Organisation has released a report on world employment and social outlook for the year 2023.

Share Market Live

NSE

The report dives into understanding the value of essential workers and analyses the working conditions of these workers — those that fall under 8 main occupational groups such as health, food systems, security, among others qualify as key workers. The findings from the report highlight a significant discrepancy between the value of work and the working conditions of key workers.

The main findings from the report show that key workers are at an increased risk of occupational safety & health. They are heavily reliant on temporary jobs and are subject to long, irregular work hours as well as low pay.

The report calls for investments into essential services, including investments in improving the working conditions of those who perform critical work.

In an interview to CNBC-, Janine Berg, Senior Economist at International Labour Organisation said contracts with workers should not be designed only to ensure lower pay, but should look at providing better working conditions.

“One can have flexibility in contractual arrangements but we want to make sure that these contractual arrangements give the same rights and benefits to workers. So the contractual arrangements should be used for flexibility but not as a means to lower pay and to lower working conditions,” Berg said.

Berg added that health workers, food vendors, security workers were subject to higher levels of verbal abuse, threats during the pandemic. According to Berg, key worker categories were more exposed to the pandemic and so had higher mortality rates.

She also emphasised that under investment in healthcare is a worldwide issue and affects working conditions in hospitals and healthcare centres.

Also Read: International Labour official reports sluggish job recovery post pandemic

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China's Shimao Group receives liquidation petition
China's Shimao Group receives liquidation petition
Jan 10, 2025
(Reuters) - China's Shimao Group ( SIOPF ) said on Friday CPYM Link Investment Limited had filed a liquidation petition against the company in the Hong Kong high court regarding a 258 million yuan ($35.19 million) cross-border loan guarantee provided by the property developer. The court has set the first hearing for the petition on March 19, 2025. This is...
Factbox-New U.S. sanctions against Russian energy interests
Factbox-New U.S. sanctions against Russian energy interests
Jan 10, 2025
(Reuters) - The U.S. Treasury on Friday announced sweeping new sanctions against the Russian energy sector, including oil majors Gazprom Neft and Surgutneftegaz, to try to hinder Moscow in its war with Ukraine. Britain also joined the sanctions against those two companies, the U.S. Treasury said. The sanctions also target more than 180 vessels and dozens of oil traders, oilfield...
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Jan 10, 2025
10:49 AM EST, 01/10/2025 (MT Newswires) -- Tyra Biosciences ( TYRA ) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer. The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly...
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
Jan 10, 2025
10:49 AM EST, 01/10/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers. This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W...
Copyright 2023-2026 - www.financetom.com All Rights Reserved